12-24 Hours
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Hapytab 50
Eskayef Pharmaceuticals Ltd.
Generic: Desvenlafaxine
Safety Advices
বাংলা
English
CAUTION
Caution is advised when consuming alcohol with Hapytab 50. Please consult your doctor.
CONSULT YOUR DOCTOR
Hapytab 50 may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
CONSULT YOUR DOCTOR
Hapytab 50 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
UNSAFE
Hapytab 50 may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
CAUTION
Hapytab 50 should be used with caution in patients with kidney disease. Dose adjustment of Hapytab 50 may be needed. Please consult your doctor.
CAUTION
Hapytab 50 should be used with caution in patients with liver disease. Dose adjustment of Hapytab 50 may be needed. Please consult your doctor.
Medicine Overview of Hapytab 50mg Tablet
Introduction
Hapytab 50 is a prescription medicine used in the treatment of depression. This medicine helps by increasing the level of chemical messengers (serotonin and noradrenaline) in the brain that have a calming effect on the brain and relax the nerves, thus treating your depression. Hapytab 50 may be taken with or without food. It is advised to take this medicine at a fixed time each day to maintain a consistent level in the blood. If you miss any doses, take it as soon as you remember. Do not skip any doses and finish the full course of treatment even if...
... Show moreUses of Hapytab 50
- Depression
Side effects of Hapytab 50
Common
- Anxiety
- Constipation
- Decreased appetite
- Dizziness
- Increased sweating
- Insomnia (difficulty in sleeping)
- Nausea
- Sexual dysfunction
- Vomiting
How to use Hapytab 50
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Hapytab 50 may be taken with or without food, but it is better to take it at a fixed time.
How Hapytab 50 works
Hapytab 50 works by increasing the levels of chemical messengers (serotonin and noradrenaline), natural substances in the brain that help maintain mental balance.
What if you forget to take Hapytab 50?
If you miss a dose of Hapytab 50, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
Quick Tips
- Ventab Dxt 50 Tablet ER helps in treating depression and anxiety.
- It may also be used to treat nerve pain from diabetes and some other forms of chronic pain.
- It may take 2 to 4 weeks for Ventab Dxt 50 Tablet ER to start working. Keep taking it as prescribed.
- It may cause dizziness and sleepiness. Do not drive or do anything requiring concentration until you know how it affects you.
- Avoid consuming alcohol when taking Ventab Dxt 50 Tablet ER as it may cause excessive drowsiness and increase the risk of liver damage.
- It may cause a sensation of restlessness, especially when you first start taking it. Inform your doctor if this happens to you.
- Talk to your doctor if you notice sudden mood changes or develop suicidal thoughts.
- Do not stop taking the medication suddenly without talking to your doctor.
Brief Description
Indication
Depression
Administration
Take whole with fluid; do not divide, crush, chew, or dissolve
Take at approximately the same time every day
Adult Dose
Oral
Depression
Adult: 50 mg once daily. Doses up to 400 mg once daily have been studied and shown to be effective, but no additional benefit was observed with doses >50 mg once daily.
Hepatic impairment: 50 mg once daily. Doses >100 mg/day are not advised.
Renal Dose
Renal impairment:
CrCl (ml/min)
30-50 mL/min 50 mg once daily.
<30 mL/min or ESRD 50 mg every other day. Additional doses should not be given after dialysis.
Contraindication
Hypersensitivity to Desvenlafaxine, venlafaxine or any component of the formulation. Concomitant/recent (within preceeding 14 days) use of MAOI. Do not initiate MAOI at least 7 days after discontinuing Desvenlafaxine.
Mode of Action
Desvenlafaxine, the major active metabolite of venlafaxine, is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). Clinical efficacy of desvenlafaxine is thought to be related with the drug's potentiation of serotonergic and noradrenergic activity in the CNS. It does not have monoamine oxidase (MAO) inhibitory activity; and has not shown significant affinity for muscarinic cholinergic, H1-histaminergic, alpha-adrenergic, dopaminergic, gama-aminobutyric acid (GABA), glutamate, and opiate receptors in vitro. At concentrations that inhibit serotonin and norephinephrine reuptake, inhibition of dopamine reuptake appears to be unlikely.
Precaution
May be associated with increased risk of suicidal thinking and behaviour in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Monitor patients for clinical worsening of depression, emergence of suicidality, unusual changes in behaviour particularly during initiation of therapy and during dosage adjustments. Serotonin syndrome or neuroleptic malignant syndrome (NMS) have occurred with selective serotonin reuptake inhibitor (SSRI) or SNRI treatment alone; and particularly with concomitant use of MAOI, serotogenic agents (e.g. triptans), antipsychotics or dopamine antagonists. Gradually taper dose if discontinuing to reduce risk of withdrawal symptoms. May activate mania/hypomania, caution in patients with...
... Show moreSide Effect
>10% Nausea (22-41%),Headache (20-29%),Dry mouth (11-25%),Hyperhidrosis (10-21%),Dizziness (13-16%),Insomnia (9-15%),Constipation (9-14%),Fatigue (7-11%),Diarrhea (5-11%) 1-10% Decreased appetite (5-10%),Anxiety (0-10%),Elevated cholesterol and triglycerides (0-10%),Insomnia (0-10%),Tremor (2-9%),Proteinuria (5-8%),Mydriasis (2-6%),Male sexual dysfunction (0-6%),Anxiety (3-5%),Vertigo (1-5%),Blurred vision (3-4%),Abnormal dreams (2-4%),Urinary hesitation (2-4%),Yawning (1-4%),Feeling jittery (1-3%),Female sexual dysfunction (0-3%),Irritability (2%) Other (eg, abnormal liver function tests, increased blood prolactin, convulsion, syncope, extrapyramidal disorders, musculoskeletal stiffness, depersonalization, hypomania, bruxism, epistaxis, orthostatic hypotension) (<2%) Asthenia (1-2%),Nervousness (1-2%),Hot flush (1-2%),Rash (1-2%) Frequency Not Defined Ischemic cardiac events in patients with multiple underlying cardiac risk factors Gastrointestinal (GI) bleeding, hallucinations, photosensitivity reactions and severe cutaneous reactions (eg, Stevens-Johnson syndrome, toxic epidermal...
... Show morePregnancy Category Note
Pregnancy No published studies on desvenlafaxine in pregnant women; however published epidemiologic studies of pregnant women exposed to venlafaxine, the parent compound, have not reported a clear association with adverse developmental outcomes Exposure to SNRIs in mid to late pregnancy may increase the risk for preeclampsia, and exposure to SNRIs near delivery may increase the risk for postpartum hemorrhage Exposure to SNRIs or SSRIs in late pregnancy may lead to an increased risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding; monitor neonates who were exposed to desvenlafaxine in the third trimester of pregnancy for drug discontinuation...
... Show moreInteraction
Desvenlafaxine may diminish the therapeutic effect of Iobenguane I-123. May enhance adverse effects of other CNS depressants. Sibutramine and MAOI may enhance the serotonergic effect of Desvenlafaxine; increase risk of development of serotonin syndrome. Concomitant use with alpha-/beta-agonists may enhance tachycardic and vasopressor effect. Desvenlafaxine may increase concentration of CYP2D6 substrates (e.g. desipramine); decrease exposure of CYP3A4 substrates (e.g. midazolam). CYP3A4 inhibitors (e.g. ketoconazole) may increase concentration of desvenlafaxine. May enhance the antiplatelet effect of nonselective NSAIDs, aspirin; and anticoagulant effect of warfarin. Potentially Fatal: Concurrent use with MAOIs may lead to fatal serotonin syndrome or NMS-like reactions. Do not...
... Show moreব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
